Gabapentin
Product Images NDC 66336-439

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 66336-439). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 66336-0439-xx (Ndc 66336 0439 Xx Westward)

This is a description of a medication called Gabapentin 300 mg, which is available as yellow capsules with the imprint "West-ward 993". It is distributed by West-Ward Pharmaceutical Corp. and the product ID is 66336-0439-XX. It should be taken orally every few hours, but may cause dizziness or drowsiness. The medication should not be taken with Maalox. The lot number is 00000, and its pedigree number is 80656366. It should be stored at 68°F and kept out of reach of children. The medication is dispensed in a tight/light resistant container, and the description includes information about how it was packaged exclusively in Santa Ana, CA 92704.*

FDA Label Image

Ndc 66336-0567-xx (Ndc 66336 0567 Xx West Ward)

This is a bulk source data for Gabapentin 100mg capsules distributed by West-Ward Pharmaceutical Corp. The product ID is grey capsule imprinted with West-ward 991. The bulk source NDC is 00143-9992-01, the MFR. Lot and pedigree numbers are not available. The medication should be dispensed in a tight/light resistant container and taken orally every specified interval. The medication may cause dizziness or drowsiness and should not be taken with Maalox. The package contains XX capsules, and the RX number is 24354696. The medication guide should be dispensed with the prescription. The product should be stored at 68°- 77° F.*

FDA Label Image

Structural Formula (Gabapentin Capsules 1)

FDA Label Image

Figure 1. Weekly Mean Pain Score (observed Cases In Itt Population): Study 1 (Gabapentin Capsules 2)

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Capsules 3)

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Capsules 4)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (Gabapentin Capsules 5)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.